UTAH MEDICAL PRODUCTS INC — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 38/100
What the filing says
UTMD reported 1H 2026 consolidated revenues of $17.3M, down 12.3% vs. 1H 2025 ($19.7M). Loss of two major customers—PendoTECH (domestic OEM) and a China distributor—accounted for $1.9M (80%) of the decline. Planned new product sales to other biopharma OEM customers materialized at only $211 in 1H 2026, falling far short of expectations. Management lowered full-year 2026 revenue guidance to a decline of 10–13% vs. 2025. Net income fell 13.1% to $5.3M despite maintained 30.7% net margin; litigation costs rose $341K in 1H. Company maintains zero debt with $87.5M cash/investments.
Why this rating
Revenue decline is meaningful (12–14% is material for a $168M company) but offset by strong cash, zero debt, healthy margins, and management's stated recovery plan. Moderate near-term headwind, not structural threat.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.